{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:42:01Z","timestamp":1790167321922,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-18339-6","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T15:30:15Z","timestamp":1758727815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The dynamic states of hepatitis B virus capsid monomers under the impact of different class of capsid-assembly modulators"],"prefix":"10.1038","volume":"15","author":[{"given":"Fatemeh Sana","family":"Askari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-585X","authenticated-orcid":false,"given":"Alireza","family":"Mohebbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"18339_CR1","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng, W. J., Papatheodoridis, G. V. & Lok, A. S. F. Hepatitis B. Lancet 401, 1039\u20131052 (2023).","journal-title":"Lancet"},{"key":"18339_CR2","doi-asserted-by":"publisher","first-page":"1356003","DOI":"10.3389\/fcimb.2024.1356003","volume":"14","author":"M Naderi","year":"2024","unstructured":"Naderi, M., Salavatiha, Z., Gogoi, U. & Mohebbi, A. An overview of anti-Hepatitis B virus flavonoids and their mechanisms of action. Front. Cell. Infect. Microbiol. 14, 1356003 (2024).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"18339_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2018.00662","volume":"9","author":"A Mohebbi","year":"2018","unstructured":"Mohebbi, A., Lorestani, N., Tahamtan, A., Kargar, N. L. & Tabarraei, A. An overview of hepatitis B virus surface antigen secretion inhibitors. Front. Microbiol. 9, 1\u20139 (2018).","journal-title":"Front. Microbiol."},{"key":"18339_CR4","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.4c08871","author":"R Kant","year":"2024","unstructured":"Kant, R. et al. Small molecule assembly agonist alters the dynamics of hepatitis B virus core protein dimer and capsid. J. Am. Chem. Soc. https:\/\/doi.org\/10.1021\/jacs.4c08871 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"18339_CR5","doi-asserted-by":"publisher","first-page":"e00680","DOI":"10.1128\/AAC.00680-17","volume":"61","author":"AM Lam","year":"2017","unstructured":"Lam, A. M. et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob. Agents Chemother. 61, e00680\u2013e00617 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"18339_CR6","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/HEP.0000000000000428","volume":"78","author":"DB Kum","year":"2023","unstructured":"Kum, D. B. et al. Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation. Hepatology 78, 1252\u20131265 (2023).","journal-title":"Hepatology"},{"key":"18339_CR7","doi-asserted-by":"crossref","unstructured":"Gane, E., Schwabe, C., Liu, J., L. S.-J. of & 2023, undefined. The safety and pharmacokinetics of ABI-4334, a novel next-generation HBV core inhibitor: interim results from a phase 1 study in healthy volunteers. https:\/\/investor.assemblybio.com\/.","DOI":"10.1016\/S0168-8278(23)03301-9"},{"key":"18339_CR8","doi-asserted-by":"publisher","first-page":"105797","DOI":"10.4254\/wjh.v17.i4.105797","volume":"17","author":"T Liu","year":"2025","unstructured":"Liu, T. et al. Drug development for chronic hepatitis B functional cure: recent progress. World J. Hepatol. 17, 105797 (2025).","journal-title":"World J. Hepatol."},{"key":"18339_CR9","doi-asserted-by":"publisher","first-page":"106010","DOI":"10.1016\/j.antiviral.2024.106010","volume":"231","author":"AM Lam","year":"2024","unstructured":"Lam, A. M. et al. Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virus. Antiviral Res. 231, 106010\u2013106010 (2024).","journal-title":"Antiviral Res."},{"key":"18339_CR10","doi-asserted-by":"crossref","unstructured":"Iyaniwura, S., Cassidy, T., & Ribeiro, R. A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B. pmc.ncbi.nlm.nih.govSA Iyaniwura, T Cassidy, RM Ribeiro, AS PerelsonbioRxiv, 2024 pmc. (2024). http:\/\/ncbi.nlm.nih.gov.","DOI":"10.1101\/2024.07.16.603658"},{"key":"18339_CR11","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.JMEDCHEM.4C01568","author":"AG Cole","year":"2024","unstructured":"Cole, A. G. et al. Rational design, synthesis, and Structure-Activity relationship of a novel Isoquinolinone-Based series of HBV capsid assembly modulators leading to the identification of clinical candidate AB-836. J. Med. Chem. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.4C01568 (2024).","journal-title":"J. Med. Chem."},{"key":"18339_CR12","doi-asserted-by":"crossref","unstructured":"Lecoq, L. et al. Molecular Elucidation of drug-induced abnormal assemblies of the hepatitis B virus capsid protein by solid-state NMR. Nat Commun 14 (2023).","DOI":"10.1038\/s41467-023-36219-3"},{"key":"18339_CR13","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1021\/acsmedchemlett.4c00388","volume":"15","author":"EF Mesaros","year":"2024","unstructured":"Mesaros, E. F. et al. Conformationally constrained isoquinolinones as orally efficacious hepatitis B capsid assembly modulators. ACS Med. Chem. Lett. 15, 1627\u20131634 (2024).","journal-title":"ACS Med. Chem. Lett."},{"key":"18339_CR14","doi-asserted-by":"crossref","unstructured":"Mohebbi, A. et al. Computer-aided drug repurposing & discovery for Hepatitis B capsid protein. In Silico Pharmacol 13, 1\u201322 (2025).","DOI":"10.1007\/s40203-025-00314-8"},{"key":"18339_CR15","first-page":"2367","volume":"15","author":"S Nayak","year":"2023","unstructured":"Nayak, S., Gowda, J., Abbas, S. A., Kim, H. & Han, S. B. Recent advances in the development of Sulfamoyl-Based hepatitis B virus nucleocapsid assembly modulators. Viruses. 15, 2367 (2023).","journal-title":"Viruses 2023"},{"key":"18339_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1021\/acsmedchemlett.0c00606","volume":"12","author":"YH Lee","year":"2021","unstructured":"Lee, Y. H. et al. Sulfamoylbenzamide-based capsid assembly modulators for selective Inhibition of hepatitis B viral replication. ACS Med. Chem. Lett. 12, 242\u2013248 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"18339_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-10200-5","volume":"10","author":"JA Kang","year":"2019","unstructured":"Kang, J. A. et al. Ciclopirox inhibits hepatitis B virus secretion by blocking capsid assembly. Nat. Commun. 10, 1\u201314 (2019).","journal-title":"Nat. Commun."},{"key":"18339_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s13337-018-00510-5","volume":"30","author":"M Rezanezhadi","year":"2019","unstructured":"Rezanezhadi, M., Mohebbi, A., Askari, F. S., Hosseini, S. D. & Tabarraei, A. Hepatitis B virus reverse transcriptase polymorphisms between treated and treatment-na\u00efve chronically infected patients. Virusdisease 30, 219\u2013226 (2019).","journal-title":"Virusdisease"},{"key":"18339_CR19","doi-asserted-by":"publisher","DOI":"10.18502\/ijml.v6i4.2013","author":"H Khani","year":"2019","unstructured":"Khani, H., Ghorbani, M., Nojoomi, F. & Mohebbi, A. Honey bee dry venom reduces hepatitis B virus surface antigen secretion in PLC\/PRF\/5 cell line. Int. J. Med. Lab. https:\/\/doi.org\/10.18502\/ijml.v6i4.2013 (2019).","journal-title":"Int. J. Med. Lab."},{"key":"18339_CR20","doi-asserted-by":"publisher","first-page":"e0316765","DOI":"10.1371\/journal.pone.0316765","volume":"20","author":"B Baei","year":"2025","unstructured":"Baei, B., Askari, P., Askari, F. S., Kiani, S. J. & Mohebbi, A. Pharmacophore modeling and QSAR analysis of anti-HBV flavonols. PLoS One. 20, e0316765 (2025).","journal-title":"PLoS One"},{"key":"18339_CR21","doi-asserted-by":"crossref","unstructured":"Hadden, J. A. et al. All-atom molecular dynamics of the HBV capsid reveals insights into biological function and cryo-EM resolution limits. Elife 7 (2018).","DOI":"10.7554\/eLife.32478"},{"key":"18339_CR22","first-page":"7420","volume":"26","author":"H Kim","year":"2021","unstructured":"Kim, H., Ko, C., Lee, J. Y. & Kim, M. Current progress in the development of hepatitis B virus capsid assembly modulators: chemical structure, Mode-of-Action and efficacy. Molecules 2021. 26, 7420 (2021).","journal-title":"Molecules 2021"},{"key":"18339_CR23","doi-asserted-by":"publisher","first-page":"16773","DOI":"10.1021\/acs.jmedchem.4c01568","volume":"67","author":"AG Cole","year":"2024","unstructured":"Cole, A. G. et al. Rational design, synthesis, and Structure-Activity relationship of a novel Isoquinolinone-Based series of HBV capsid assembly modulators leading to the identification of clinical candidate AB-836. J. Med. Chem. 67, 16773\u201316795 (2024).","journal-title":"J. Med. Chem."},{"key":"18339_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.16.603658","author":"SA Iyaniwura","year":"2024","unstructured":"Iyaniwura, S. A., Cassidy, T., Ribeiro, R. M. & Perelson, A. S. A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B. BioRxiv https:\/\/doi.org\/10.1101\/2024.07.16.603658 (2024).","journal-title":"BioRxiv"},{"key":"18339_CR25","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1128\/AAC.01766-12","volume":"57","author":"L Li","year":"2013","unstructured":"Li, L., Chirapu, S. R., Finn, M. G. & Zlotnick, A. Phase diagrams map the properties of antiviral agents directed against hepatitis B virus core assembly. Antimicrob. Agents Chemother. 57, 1505\u20131508 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"18339_CR26","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1128\/JVI.76.10.4848-4854.2002","volume":"76","author":"A Zlotnick","year":"2002","unstructured":"Zlotnick, A., Ceres, P., Singh, S. & Johnson, J. M. A small molecule inhibits and misdirects assembly of hepatitis B virus capsids. J. Virol. 76, 4848 (2002).","journal-title":"J. Virol."},{"key":"18339_CR27","doi-asserted-by":"crossref","unstructured":"Ma, Y. et al. Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing Spiro ring as hepatitis B virus capsid protein inhibitors. Eur J. Med. Chem 225, (2021).","DOI":"10.1016\/j.ejmech.2021.113780"},{"key":"18339_CR28","doi-asserted-by":"crossref","unstructured":"Huber, A. D. et al. The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells. mSphere 3 (2018).","DOI":"10.1128\/mSphereDirect.00131-18"},{"key":"18339_CR29","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1021\/acs.jmedchem.1c02040","volume":"65","author":"A Pavlova","year":"2022","unstructured":"Pavlova, A. et al. Mechanism of action of HBV capsid assembly modulators can be predicted from binding to early assembly intermediates. J. Med. Chem. 65, 4854 (2022).","journal-title":"J. Med. Chem."},{"key":"18339_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymeth.2012.04.005","volume":"57","author":"J \u0160poner","year":"2012","unstructured":"\u0160poner, J., Cang, X. & Cheatham, T. E. Molecular dynamics simulations of G-DNA and perspectives on the simulation of nucleic acid structures. Methods 57, 25 (2012).","journal-title":"Methods"},{"key":"18339_CR31","doi-asserted-by":"publisher","first-page":"10225","DOI":"10.1021\/jp103944q","volume":"114","author":"DL Chen","year":"2010","unstructured":"Chen, D. L., Stern, A. C., Space, B. & Johnson, J. K. Atomic charges derived from electrostatic potentials for molecular and periodic systems. J. Phys. Chem. A. 114, 10225\u201310233 (2010).","journal-title":"J. Phys. Chem. A"},{"key":"18339_CR32","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1021\/acs.jctc.6b00209","volume":"12","author":"MJ Van Vleet","year":"2016","unstructured":"Van Vleet, M. J., Misquitta, A. J., Stone, A. J. & Schmidt, J. R. Beyond Born-Mayer: improved models for Short-Range repulsion in Ab initio force fields. J. Chem. Theory Comput. 12, 3851\u20133870 (2016).","journal-title":"J. Chem. Theory Comput."},{"key":"18339_CR33","doi-asserted-by":"crossref","unstructured":"Lin, J. et al. Bay41-4109-induced aberrant polymers of hepatitis b capsid proteins are removed via STUB1-promoted p62-mediated macroautophagy. PLoS Pathog 18 (2022).","DOI":"10.1371\/journal.ppat.1010204"},{"key":"18339_CR34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ejmech.2019.01.059","volume":"166","author":"T Pan","year":"2019","unstructured":"Pan, T. et al. Design and synthesis of aminothiazole based hepatitis B virus (HBV) capsid inhibitors. Eur. J. Med. Chem. 166, 480\u2013501 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"18339_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.antiviral.2016.11.026","volume":"137","author":"J Tu","year":"2017","unstructured":"Tu, J., Li, J. J., Shan, Z. J. & Zhai, H. L. Exploring the binding mechanism of heteroaryldihydropyrimidines and hepatitis B virus capsid combined 3D-QSAR and molecular dynamics. Antiviral Res. 137, 151\u2013164 (2017).","journal-title":"Antiviral Res."},{"key":"18339_CR36","doi-asserted-by":"crossref","unstructured":"Su, P. Y. et al. HBV maintains electrostatic homeostasis by modulating negative charges from phosphoserine and encapsidated nucleic acids. Sci. Rep. 6, 1\u201319 (2016).","DOI":"10.1038\/srep38959"},{"key":"18339_CR37","doi-asserted-by":"publisher","first-page":"11055","DOI":"10.1128\/JVI.00933-06","volume":"80","author":"CR Bourne","year":"2006","unstructured":"Bourne, C. R., Finn, M. G. & Zlotnick, A. Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J. Virol. 80, 11055\u201311061 (2006).","journal-title":"J. Virol."},{"key":"18339_CR38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3851\/IMP2152","volume":"17","author":"XY Wang","year":"2012","unstructured":"Wang, X. Y. et al. In vitro Inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther. 17, 793\u2013803 (2012).","journal-title":"Antivir Ther."},{"key":"18339_CR39","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S1097-2765(01)80009-5","volume":"3","author":"SA Wynne","year":"1999","unstructured":"Wynne, S. A., Crowther, R. A. & Leslie, A. G. W. The crystal structure of the human hepatitis B virus capsid. Mol. Cell. 3, 771\u2013780 (1999).","journal-title":"Mol. Cell."},{"key":"18339_CR40","doi-asserted-by":"crossref","unstructured":"de Rocquigny, H. et al. Phosphorylation of the arginine-rich C-terminal domains of the hepatitis B virus (HBV) core protein as a fine regulator of the interaction between HBc and nucleic acid. Viruses 12 (2020).","DOI":"10.3390\/v12070738"},{"key":"18339_CR41","doi-asserted-by":"crossref","unstructured":"Motlagh, H. N., Wrabl, J. O., Li, J. & Hilser, V. J. The ensemble nature of allostery. Nature 508, 331\u2013339 (2014).","DOI":"10.1038\/nature13001"},{"key":"18339_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0076-6879(08)04214-6","volume":"455","author":"S Katen","year":"2009","unstructured":"Katen, S. & Zlotnick, A. The thermodynamics of virus capsid assembly. Methods Enzymol. 455, 395\u2013417 (2009).","journal-title":"Methods Enzymol."},{"key":"18339_CR43","doi-asserted-by":"crossref","unstructured":"Kim, C. et al. Core Protein-Directed antivirals and importin \u03b2 can synergistically disrupt hepatitis B virus capsids. J. Virol. 96, (2022).","DOI":"10.1128\/JVI.01395-21"},{"key":"18339_CR44","doi-asserted-by":"crossref","unstructured":"Zhou, Z. et al. Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms. Sci. Rep. 7, (2017).","DOI":"10.1038\/srep42374"},{"key":"18339_CR45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s13337-016-0333-9","volume":"27","author":"A Mohebbi","year":"2016","unstructured":"Mohebbi, A., Mohammadi, S. & Memarian, A. Prediction of HBF-0259 interactions with hepatitis B virus receptors and surface antigen secretory factors. Virusdisease 27, 234\u2013241 (2016).","journal-title":"Virusdisease"},{"key":"18339_CR46","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2217\/fvl-2020-0394","volume":"16","author":"A Mohebbi","year":"2021","unstructured":"Mohebbi, A., Askari, F. S., Sammak, A. S., Ebrahimi, M. & Najafimemar, Z. Druggability of cavity pockets within SARS-CoV-2 Spike glycoprotein and pharmacophore-based drug discovery. Future Virol. 16, 389\u2013397 (2021).","journal-title":"Future Virol."},{"key":"18339_CR47","doi-asserted-by":"publisher","unstructured":"Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F. & Hermans, J. Interaction models for water in relation to protein hydration. Intermolecular Forces: Proceedings of the Fourteenth Jerusalem Symposium on Quantum Chemistry and Biochemistry Held in Jerusalem, Israel, April 13\u201316. 331\u2013342. https:\/\/doi.org\/10.1007\/978-94-015-7658-1_21 (1981).","DOI":"10.1007\/978-94-015-7658-1_21"},{"key":"18339_CR48","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jcc.21367","volume":"31","author":"K Vanommeslaeghe","year":"2010","unstructured":"Vanommeslaeghe, K. et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671\u2013690 (2010).","journal-title":"J. Comput. Chem."},{"key":"18339_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.52547\/jcbr.5.2.26","volume":"5","author":"A Mohebbi","year":"2021","unstructured":"Mohebbi, A., Mirarab, A., Shaddel, R., Shafaei Fallah, M. & Memarian, A. Molecular dynamic simulation and Docking of Cyclophilin A mutants with its potential inhibitors. J. Clin. Basic. Res. 5, 26\u201341 (2021).","journal-title":"J. Clin. Basic. Res."},{"key":"18339_CR50","doi-asserted-by":"crossref","unstructured":"Mohebbi, A. Ligand-based 3D pharmacophore modeling, virtual screening, and molecular dynamic simulation of potential smoothened inhibitors. J Mol. Model 29 (2023).","DOI":"10.1007\/s00894-023-05532-5"},{"key":"18339_CR51","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2022-0054","author":"FS Askari","year":"2022","unstructured":"Askari, F. S. et al. Digging for the discovery of SARS-CoV-2 nsp12 inhibitors: a pharmacophore-based and molecular dynamics simulation study. Future Virol. https:\/\/doi.org\/10.2217\/fvl-2022-0054 (2022).","journal-title":"Future Virol."},{"key":"18339_CR52","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2246583","author":"M Samantaray","year":"2024","unstructured":"Samantaray, M. et al. Structure-based virtual screening of natural compounds against wild and mutant (R1155K, A1156T and D1168A) NS3-4A protease of hepatitis C virus. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2023.2246583 (2024).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"18339_CR53","doi-asserted-by":"crossref","unstructured":"Das, E. et al. Development of a Multiple-Epitope-Based Vaccine for Hepatitis C Virus Genotypes 1a and 1b: an in-silico reverse vaccinology approach. In Silico Pharmacol. 12, 1\u201316 (2024).","DOI":"10.1007\/s40203-024-00275-4"},{"key":"18339_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-024-09523-6","volume":"24","author":"A Mohebbi","year":"2024","unstructured":"Mohebbi, A. et al. Dental complications as a potential indicator of redondovirus infection: a cross-sectional study. BMC Infect. Dis. 24, 1\u201312 (2024).","journal-title":"BMC Infect. Dis."},{"key":"18339_CR55","doi-asserted-by":"publisher","first-page":"1572274","DOI":"10.3389\/froh.2025.1572274","volume":"6","author":"A Mohebbi","year":"2025","unstructured":"Mohebbi, A. et al. Redondovirius-associated periodontitis in people with poor oral hygiene: a cross-sectional study. Front. Oral Health. 6, 1572274 (2025).","journal-title":"Front. Oral Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18339-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18339-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18339-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T15:30:20Z","timestamp":1758727820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-18339-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["18339"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-18339-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6244861\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32731"}}